Skip to main content

Table 3 Association of IVIG treatment with mortality among sub-groups

From: Clinical outcomes of intravenous immunoglobulin therapy in COVID-19 related acute respiratory distress syndrome: a retrospective cohort study

Sub-groups

sHR (95% confidence interval)

P value

PaO2/FiO2 ratio

  

> 100 mm Hg

3.44 (2.04–5.78)

 < 0.001

≤ 100 mm Hg

2.17 (1.07–4.41)

0.03

Serum ferritin level

  

< 1000 mcg/L

3.45 (1.87–6.38)

 < 0.001

≥ 1000 mcg/L

2.79 (1.52–5.11)

0.001

Time from ICU admission to IVIG therapy

  

< 5 days

2.65 (1.07–6.56)

0.035

≥ 5 days

3.89 (1.85–8.18)

 < 0.001

Number of IVIG doses received

  

≤ 3 doses

3.72 (1.39–9.91)

0.009

> 3 doses

3.42 (1.69–6.93)

0.001

  1. IVIG, intravenous immunoglobulin; sHR, sub-distribution hazard ratio; PaO2/FiO2 ratio, ratio of partial pressure arterial oxygen and fraction of inspired oxygen; mcg/L, microgram per liter